Overview
Theraclion is a French medical technology company specializing in the development of innovative ultrasound solutions for the treatment of thyroid nodules and breast fibroadenomas. The company's flagship product, Echopulse, uses high-intensity focused ultrasound (HIFU) to provide non-invasive treatment options for patients. This technology enables a precise focus on the target tissue without affecting the surrounding healthy tissue.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for Theraclion SA as of December 31, 2024 is 0.83 MM.
- The operating income for Theraclion SA as of December 31, 2024 is -6.82 MM.
- The net income for Theraclion SA as of December 31, 2024 is -5.76 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2024-12-31 | 0.83 | -6.82 | -5.76 |
2024-09-30 | 0.72 | -5.23 | -5.00 |
2024-06-30 | 0.60 | -3.64 | -4.24 |
2024-03-31 | 1.21 | -3.40 | -3.96 |
2023-12-31 | 1.82 | -3.15 | -3.68 |
2023-09-30 | 1.85 | -4.60 | -4.28 |
2023-06-30 | 1.87 | -6.04 | -4.88 |
2023-03-31 | 1.55 | -6.18 | -4.92 |
2022-12-31 | 1.24 | -6.31 | -4.96 |
2022-09-30 | 0.99 | -6.27 | -4.83 |
2022-06-30 | 0.74 | -6.24 | -4.69 |
2022-03-31 | 1.11 | -5.39 | -4.23 |
2021-12-31 | 1.48 | -4.53 | -3.76 |
2021-09-30 | 1.57 | -4.23 | -3.71 |
2021-06-30 | 1.67 | -3.92 | -3.66 |
2021-03-31 | 1.20 | -4.10 | -3.78 |
2020-12-31 | 0.74 | -4.29 | -3.91 |
2020-09-30 | 1.37 | -4.44 | -3.95 |
Income Statement: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | -0.08 | |
2023-09-30 | -0.09 | -0.09 |
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | -0.16 | |
2022-09-30 | -0.16 | -0.16 |
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | -0.17 | |
2021-09-30 | -0.16 | -0.16 |
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | -0.24 | |
2020-09-30 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Theraclion SA as of December 31, 2024 is -2.91 MM.
- The cash from investing activities for Theraclion SA as of December 31, 2024 is -0.19 MM.
- The cash from financing activities for Theraclion SA as of December 31, 2024 is -0.55 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2024-12-31 | -2.91 | -0.19 | -0.55 |
2024-09-30 | -2.74 | -0.14 | -0.55 |
2024-06-30 | -2.57 | -0.09 | -0.55 |
2024-03-31 | -2.53 | -0.15 | 3.72 |
2023-12-31 | -2.48 | -0.21 | 7.99 |
2023-09-30 | -2.76 | -0.33 | 7.93 |
2023-06-30 | -3.04 | -0.46 | 7.86 |
2023-03-31 | -4.15 | -0.60 | 6.94 |
2022-12-31 | -5.27 | -0.74 | 6.03 |
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | -3.88 | -0.52 | 4.56 |
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | -3.32 | -0.19 | 4.41 |
2020-09-30 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 |
Management Effectiveness
- The roa for Theraclion SA as of December 31, 2024 is -0.19.
- The roe for Theraclion SA as of December 31, 2024 is -0.63.
- The roic for Theraclion SA as of December 31, 2024 is -0.32.
- The croic for Theraclion SA as of December 31, 2024 is -0.29.
- The ocroic for Theraclion SA as of December 31, 2024 is -0.23.
Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
2024-12-31 | -0.19 | -0.63 | -0.32 | -0.29 | -0.23 |
2024-09-30 | -0.20 | -0.65 | |||
2024-06-30 | -6.64 | ||||
2024-03-31 | -6.74 | ||||
2023-12-31 | -0.76 | 0.86 | |||
2023-09-30 | -0.74 | 0.67 | |||
2023-06-30 | |||||
2023-03-31 | |||||
2022-12-31 | |||||
2022-09-30 | 0.00 | ||||
2022-06-30 | |||||
2022-03-31 | |||||
2021-12-31 | |||||
2021-09-30 | -0.35 | ||||
2021-06-30 | -0.35 | -0.35 | 0.08 | -0.31 | |
2021-03-31 | -0.36 | -0.51 | 0.12 | -0.45 | |
2020-12-31 | -0.37 | -0.53 | 0.12 | -0.45 | |
2020-09-30 | -0.38 | -0.54 | 0.07 | -0.50 |
Gross Margins
- The gross margin for Theraclion SA as of December 31, 2024 is -1.10.
- The net margin for Theraclion SA as of December 31, 2024 is -2.44.
- The operating margin for Theraclion SA as of December 31, 2024 is -2.03.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
2024-12-31 | -1.10 | -2.44 | -2.03 |
2024-09-30 | 0.92 | -0.94 | -0.81 |
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | -2.62 | -3.25 | |
2023-06-30 | -2.62 | -3.25 | |
2023-03-31 | -3.18 | -3.99 | |
2022-12-31 | |||
2022-09-30 | 0.00 | 0.00 | |
2022-06-30 | 0.00 | 0.00 | |
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | -1.32 | -2.20 | -2.35 |
2021-03-31 | -1.53 | -3.14 | -3.40 |
2020-12-31 | -2.03 | -5.27 | -5.79 |
2020-09-30 | -1.03 | -2.89 | -3.25 |
Identifiers and Descriptors
Central Index Key (CIK) |
Industry Groups
SIC 3845 - Electromedical and Electrotherapeutic Apparatus |